Decoy Therapeutics is trading 6.2% up today at $4.29 as the stock extends its rebound following positive lab results for its antiviral platform against Ebola Zaire.
- The move follows a July 28 report highlighting successful lab testing, which previously triggered a sharp two-day rally despite ongoing execution concerns.
- The stock continues to recover from a steep drop on July 27, even as broader biotech sector weakness and cautious risk sentiment provide a modest offset.